Cite
HARVARD Citation
Dimopoulos, M. et al. (n.d.). Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet oncology. 17 (1), pp. 27-38. [Online].